PM David Cameron opens e-Therapeutics’ drug discovery centre

Network Pharmacology Centre will search for novel treatments for cancer and CNS diseases

UK drug discovery and development firm e-Therapeutics has opened a new drug discovery centre at Long Hanborough, near Oxford.

The Network Pharmacology Centre will focus on searching for novel treatments for cancer and degenerative diseases of the nervous system.

UK Prime Minister David Cameron officially opened the centre.

He said: ‘e-Therapeutics is a fascinating and innovative business in my constituency. Their use of pioneering science has the potential to deliver great results and I very much hope that their treatments are successful.’

Professor Malcolm Young, founder and chief executive of e-Therapeutics, added: ‘We are delighted to have the Prime Minister open our new drug discovery centre near Oxford, which is a world centre of excellence in the science that underpins our business.’

The new centre will spearhead e-Therapeutics’ pioneering work in network pharmacology, which involves application of network analysis to determine the set of proteins most critical in any disease, and then chemical biology to identify molecules capable of targeting that set of proteins.

The firm says by addressing the true complexity of disease and by seeking to harness the ability of drugs to influence many different proteins, network pharmacology differs from conventional drug discovery approaches, which have generally been based on highly specific targeting of a single protein.

During 2012, e-Therapeutics plans to advance four drugs derived from network pharmacology research into clinical trials. These include potential treatments for cancer, major depressive disorder and resistant bacterial infections.

The firm’s headquarters are in Newcastle-upon-Tyne.

You may also like

Ingredients

e-therapeutics launches anti-viral drug discovery initiative for COVID-19

UK-based e-therapeutics discusses the moral responsibility of business and reaches out for aid with a network-driven drug discovery platform to help the current pandemic
Research & Development

Could machine learning present a paradigm shift in drug discovery?

Angharad Baldwin catches up with Dr Raymond Barlow, CEO at e-therapeutics, about what network-driven drug discovery can offer the pharmaceutical industry in its pursuit of new medicines
Research & Development

Collaboration to enhance and extend AI technology capabilities

e-Therapeutics, a company pioneering the use of network-driven drug discovery (NDD) to create new and better drugs, announced agreements with Intellegens and Biorelate to develop artificial intelligence (AI) technology capabilities
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Subscribe now